Abstract
BackgroundThe ABSORB bioresorbable vascular scaffold (BVS) was withdrawn from market due to a greater risk of early target lesion failure (TLF) to 3 years. It was hypothesised that once the...
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
